Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses updated overall survival results on cabozantinib vs sunitinib as initial targeted treatment for patients with metastatic renal cell carcinoma (Abstract LBA38).
Luis G. Paz-Ares, MD, PhD, of Hospital Universitario 12 De Octubre, discusses phase III study findings on durvalumab after chemoradiation therapy in patients with stage III, locall...
Caroline Robert, MD, PhD, of Gustave Roussy, characterizes complete responses in patients with advanced melanoma who received the combination of nivolumab and ipilimumab, or nivolu...
Eric Pujade-Lauraine, MD, PhD, of the Université Paris Descartes, discusses phase III study findings on the efficacy of olaparib maintenance therapy in patients with platinum-sensi...
Jaafar Bennouna, MD, of the University of Nantes, discusses findings from a phase II French study of bevacizumab or cetuximab plus chemotherapy after progression with bevacizumab p...
Robert I. Haddad, MD, of Dana-Farber Cancer Institute, discusses phase III study results on treatment beyond disease progression with nivolumab in patients with recurrent or metast...